The B-D44 monoclonal antibody specifically recognizes CD263 which is also known as, TNF-related apoptosis-inducing ligand receptor 3 (TRAIL Receptor 3/TRAIL-R3), Decoy receptor 1 (DCR1), Lymphocyte inhibitor of TRAIL (LIT), or TRID. CD263 is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein that belongs to the TNF Receptor Superfamily which includes other TRAIL (CD253/APO-2 Ligand) Receptors: CD261 (TRAIL-R1), CD262 (TRAIL-R2), and CD264 (TRAIL-R4). Unlike CD261 or CD262 that contain an intracellular signaling death domain, CD263 (and CD264) lacks a cytoplasmic death domain and is unable to transduce apoptotic signals upon binding TRAIL. CD263 thus serves as a decoy receptor for TRAIL. It functions as a negative regulator of apoptotic signaling by competing with CD261 and CD262 for the binding of TRAIL. Overexpression of CD263 can reportedly attenuate TRAIL-induced apoptosis.
This antibody is conjugated to BD Horizon™ BV605 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max of 407-nm and Em Max of 602-nm, BD Horizon BV605 can be excited by a violet laser and detected with a standard 610/20-nm filter set. BD Horizon BV605 is a tandem fluorochrome of BD Horizon BV421 and an acceptor dye with an Em max at 605-nm. Due to the excitation of the acceptor dye by the green (532 nm) and yellow-green (561 nm) lasers, there will be significant spillover into the PE and BD Horizon PE-CF594 detectors off the green or yellow-green lasers. BD Horizon BV605 conjugates are very bright, often exhibiting brightness equivalent to PE conjugates and can be used as a third color off of the violet laser.